NCT06709404 Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers
| NCT ID | NCT06709404 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Hematopoietic and Lymphatic System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-01-31 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-01-31 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial assesses whether resource identification for primary caregivers can affect financial stress, quality of life, depression, and the general belief in the ability to cope with daily life. Caregivers of patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS+HIPEC) demonstrate that they endure high depressive symptom burdens and financial distress. Further, they experience symptom trajectories that differ from those of patients. In short, they require differential timing of supportive interventions. This study aims to reduce financial toxicity and distress levels and to increase self-efficacy, satisfaction and engagement with care. Information gathered from this study may help researchers determine whether telehealth interventions for caregivers may increase awareness of recommended resources that could be beneficial during caregivers journey.
Eligibility Criteria
Inclusion Criteria * Primary caregiver of a patient scheduled to receive CS+HIPEC at Atrium Health Wake Forest Baptist Comprehensive Cancer Center * Access to a computer or smartphone and must have an email address * 18 years of age or older at the time of consent * The ability to understand and willingness to provide written informed consent * The ability to read and write English Exclusion Criteria \- Patient declines access to their medical record
Contact & Investigator
Katie Duckworth
PRINCIPAL INVESTIGATOR
Wake Forest Baptist Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06709404 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphatic System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06709404 currently recruiting?
Yes, NCT06709404 is actively recruiting participants. Contact the research team at Emily.Teal@advocatehealth.org for enrollment information.
Where is the NCT06709404 trial being conducted?
This trial is being conducted at Winston-Salem, United States.
Who is sponsoring the NCT06709404 clinical trial?
NCT06709404 is sponsored by Wake Forest University Health Sciences. The principal investigator is Katie Duckworth at Wake Forest Baptist Comprehensive Cancer Center. The trial plans to enroll 50 participants.